QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
2,090.00 1,978.21 1,965.31 2,141.52 2,251.66 1,870.35 1,526.42 1,501.85 1,417.54 1,337.99
Revenue Growth
5.65% 0.66% (8.23%) (4.89%) 20.39% 22.53% 1.64% 5.95% 5.95% 4.45%
Cost of Revenue
790.50 1,010.86 731.62 756.96 800.84 637.63 521.16 500.89 494.98 493.34
Gross Profit
1,299.50 967.35 1,233.69 1,384.56 1,450.82 1,232.72 1,005.26 1,000.96 922.56 844.65
R&D Expenses
187.52 193.49 198.51 189.86 189.96 149.07 157.45 161.85 154.08 149.84
SG&A Expenses
583.67 564.36 579.17 603.95 584.47 525.36 504.17 496.85 575.66 556.89
Operating Income
465.85 97.71 409.94 531.46 630.08 386.43 (26.14) 266.58 153.42 98.83
Non-operating Income/Expense
24.41 23.44 19.87 (18.86) (4.25) 53.04 (51.64) (40.84) (39.04) (41.92)
Non-operating Interest Expenses
33.26 43.84 53.41 58.36 54.48 71.32 74.19 67.29 49.69 39.02
EBT
490.27 121.15 429.81 512.60 625.83 439.47 (77.78) 225.74 114.38 56.91
Income Tax Provision
65.39 37.56 88.51 89.39 113.23 80.28 (36.32) 35.36 73.98 (23.39)
Income after Tax
424.88 83.59 341.30 423.21 512.60 359.19 (41.45) 190.38 40.39 80.30
Non-Controlling Interest
— — — — — — — — — (0.10)
Net Income Common
424.88 83.59 341.30 423.21 512.60 359.19 (41.45) 190.38 40.39 80.40
EPS (Basic)
1.94 0.39 1.60 2.05 2.47 1.71 (0.20) 0.92 0.19 0.38
EPS (Diluted)
1.94 0.39 1.60 2.05 2.47 1.71 (0.20) 0.92 0.19 0.38
Shares (Basic, Weighted)
217.22 222.62 216.74 210.19 204.25 204.64 203.17 203.04 204.33 210.35
Shares (Diluted, Weighted)
218.88 224.72 219.09 212.55 207.88 209.83 203.17 209.15 208.75 214.11
Gross Margin
62.18% 48.90% 62.77% 64.65% 64.43% 65.91% 65.86% 66.65% 65.08% 63.13%
EBIT Margin
22.29% 4.94% 20.86% 24.82% 27.98% 20.66% (1.71%) 17.75% 10.82% 7.39%
EBT margin
23.46% 6.12% 21.87% 23.94% 27.79% 23.50% (5.10%) 15.03% 8.07% 4.25%
Net Profit Margin
20.33% 4.23% 17.37% 19.76% 22.77% 19.20% (2.72%) 12.68% 2.85% 6.01%
Free Cash Flow Margin
21.40% 25.39% 15.09% 26.43% 19.21% 8.21% 3.67% 13.90% 11.46% 18.52%
EBITDA
662.96 319.41 645.44 773.56 877.31 633.76 246.09 508.55 394.64 332.33
EBIT
465.85 97.71 409.94 531.46 630.08 386.43 (26.14) 266.58 153.42 98.83
Income from Continuous Operations
424.88 83.59 341.30 423.21 512.60 359.19 (41.45) 190.38 40.39 80.30
Consolidated Net Income/Loss
424.88 83.59 341.30 423.21 512.60 359.19 (41.45) 190.38 40.39 80.30
EPS (Basic, from Continuous Ops)
1.96 0.38 1.57 2.01 2.51 1.76 (0.20) 0.94 0.20 0.38
EPS (Basic, Consolidated)
1.96 0.38 1.57 2.01 2.51 1.76 (0.20) 0.94 0.20 0.38
EPS (Diluted, from Cont. Ops)
1.94 0.37 1.56 1.99 2.47 1.71 (0.20) 0.91 0.19 0.38
Shares (Diluted, Average)
218.88 213.48 213.00 206.18 207.88 209.83 208.22 209.15 208.75 214.12
EPS (Diluted, Consolidated)
1.94 0.37 1.56 1.99 2.47 1.71 (0.20) 0.91 0.19 0.38
EBITDA Margin
31.72% 16.15% 32.84% 36.12% 38.96% 33.88% 16.12% 33.86% 27.84% 24.84%
Operating Cash Flow Margin
31.31% 34.05% 23.38% 33.40% 28.38% 24.48% 21.67% 23.94% 20.23% 25.53%

Fold the line items

In millions of $ except per-share values · columns are period end dates